<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03280901</url>
  </required_header>
  <id_info>
    <org_study_id>HD-Remodel-UK-01</org_study_id>
    <secondary_id>IRAS 207142</secondary_id>
    <nct_id>NCT03280901</nct_id>
  </id_info>
  <brief_title>HaemoDialysis Interventions to REduce Multi-Organ Dysfunction and Effect on Quality of Life Assessed by MRI Scanning</brief_title>
  <acronym>HD-REMODEL</acronym>
  <official_title>HaemoDialysis Interventions to REduce Multi-Organ Dysfunction and Effect on Quality of Life (HD-REMODEL) Assessed by MRI Scanning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterise in detail cardiac, cerebral and renal structure,&#xD;
      function and perfusion in patients on haemodialysis (HD) using magnetic imaging techniques.&#xD;
      The effects of a standard prescription haemodialysis (dialysate temperature 37 C) will be&#xD;
      compared to a thermocontrolled (or isothermic) haemodialysis prescription to ascertain if&#xD;
      thermocontrolled HD provides a protective effect on organ perfusion and circulatory stress&#xD;
      when compared to conventional haemodialysis. The BTM (blood temperature monitor, Fresenius)&#xD;
      offers a way to overcome this to regulate thermal balance during dialysis and achieve a&#xD;
      neutral thermal balance (isothermic) over the dialysis session. Other dialysis parameters&#xD;
      will be standardised between treatment arms using blood volume monitoring (BVM) and clinical&#xD;
      assessments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to characterise in detail cardiac, cerebral and renal structure,&#xD;
      function and perfusion in patients on haemodialysis (HD) using magnetic imaging techniques.&#xD;
      The Primary objectives are to investigate the difference in cardiac perfusion, structure and&#xD;
      function between standard HD and thermocontrolled HD using magnetic imaging techniques, to&#xD;
      observe the the changes in renal perfusion and oxygenation within one dialysis session and&#xD;
      the changes to cerebral perfusion within one dialysis session.&#xD;
&#xD;
      The secondary objectives are to investigate the difference in cerebral perfusion, structure,&#xD;
      oedema and function between standard HD and thermocontrolled HD, the difference in renal&#xD;
      perfusion and oxygenation between standard HD and thermocontrolled HD and the differences in&#xD;
      visual acuity and cognitive assessment across a dialysis session and over a dialysis&#xD;
      treatment course.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Actual">August 20, 2020</completion_date>
  <primary_completion_date type="Actual">May 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>monocentric, block randomized, open, crossover study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cardiac output during standard HD and thermocontrolled HD</measure>
    <time_frame>after 2 and 4 weeks after randomisation</time_frame>
    <description>Change in cardiac output during standard HD and thermocontrolled HD using Phase Contrast Magnetic Resonance Imaging (PC-MRI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in renal perfusion during standard HD and thermocontrolled HD</measure>
    <time_frame>after 2 and 4 weeks after randomisation</time_frame>
    <description>Change in renal perfusion using Arterial Spin Labelling (ASL) and renal artery flow using PC-MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cerebral perfusion during standard HD and thermocontrolled HD</measure>
    <time_frame>after 2 and 4 weeks after randomisation</time_frame>
    <description>Change in cerebral perfusion during standard HD and thermocontrolled HD using ASL</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Renal Failure</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Congenital Disorders</condition>
  <arm_group>
    <arm_group_label>Standard HD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HD with constant temperature of 37°C, MRI scans of the heart, kidneys and brain during HD sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thermocontrolled HD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HD applying the Blood Temperature Monitor (BTM), MRI scans of the heart, kidneys and brain during HD sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HD, Magnetic Resonance Imaging (MRI) scans</intervention_name>
    <description>HD, Magnetic Resonance Imaging (MRI) scans using a specifically designed unit able to perform MRI scanning during HD sessions</description>
    <arm_group_label>Standard HD</arm_group_label>
    <arm_group_label>Thermocontrolled HD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria:&#xD;
&#xD;
          -  Change in dry weight (clinically defined) in 4 weeks prior to recruitment&#xD;
&#xD;
          -  Dialysate composition other than: sodium≥137mmol/L, potassium≥2.0mmol/L,&#xD;
             calcium≥1.5mmol/L, magnesium≥0.5mmol/L, glucose 1.0g/L&#xD;
&#xD;
          -  Instability on dialysis in 4 weeks prior to recruitment leading to either:&#xD;
&#xD;
               -  Emergency medical attention&#xD;
&#xD;
               -  Infusion of additional fluid&#xD;
&#xD;
               -  Loss in consciousness&#xD;
&#xD;
               -  Arrhythmia&#xD;
&#xD;
               -  Chest pain&#xD;
&#xD;
               -  Or any other medical condition that precludes the scan session in opinion of the&#xD;
                  investigator&#xD;
&#xD;
          -  Dialysed via a synthetic line, central venous catheter or graft&#xD;
&#xD;
          -  Qa &lt; 500ml/min&#xD;
&#xD;
          -  NYHA Stage IV heart failure (New York Heart Association)&#xD;
&#xD;
          -  Active infection or malignancy&#xD;
&#xD;
          -  Contraindication to MRI scanning including claustrophobia, pacemaker, metallic&#xD;
             implants etc&#xD;
&#xD;
          -  Pregnancy (pregnancy test will be conducted with female patients aged ≤ 55 years) or&#xD;
             planning pregnancy or lactation period&#xD;
&#xD;
          -  Medical conditions or overall physical frailty precludes scan session in opinion of&#xD;
             investigator&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent&#xD;
&#xD;
          -  Any condition which could interfere with the patient's ability to comply with the&#xD;
             study&#xD;
&#xD;
          -  Participation in an interventional clinical study during the preceding 30 days&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80, male and female&#xD;
&#xD;
          -  Informed consent signed and dated by study patient and investigator/authorised&#xD;
             physician&#xD;
&#xD;
          -  Average (4 weeks prior to recruitment) Ultrafiltration volumes ≥ 0.5 litres/ dialysis&#xD;
             session&#xD;
&#xD;
          -  Receiving dialysis via an arteriovenous fistula&#xD;
&#xD;
          -  Must be able to follow simple instruction in English (on safety grounds for MRI scans)&#xD;
             and be able to understand the nature and requirements of the study&#xD;
&#xD;
          -  Stable dialysis prescription&#xD;
&#xD;
          -  CKD5 (Chronic kidney disease) patients having renal replacement therapy with&#xD;
             haemodialysis/ haemodiafiltration (&gt;90 days)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maarten Taal, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Nottingham, Division of Medical Sciences and Graduate Entry Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Selby, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nottingham, Division of Medical Sciences and Graduate Entry Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nottingham, Division of Medical Sciences and Graduate Entry Medicine</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 28, 2017</study_first_submitted>
  <study_first_submitted_qc>September 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2017</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal replacement therapy</keyword>
  <keyword>haemodialysis</keyword>
  <keyword>haemodiafiltration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

